Arcturus Therapeutics Signals Progress Amid Revenue Slip

Arcturus Therapeutics ((ARCT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Arcturus Therapeutics’ latest earnings call struck a cautiously upbeat tone as management balanced clear scientific momentum with financial headwinds. Executives highlighted meaningful clinical and regulatory progress, a reinforced leadership bench and a cash runway into mid‑2028, while acknowledging revenue declines, rising program costs and lingering risks around a small cystic fibrosis study and the nascent inhaled mRNA modality.

ARCT‑032 Steps Into a 12‑Week Phase II Trial

Arcturus has advanced ARCT‑032, its inhaled mRNA therapy for cystic fibrosis, into a 12‑week open‑label Phase II study that began enrolling in the first quarter of 2026. The trial, which allows up to about 20 participants and expands to sites outside the U.S., is designed to move beyond prior 28‑day exposures and track changes in FEV1, lung clearance index, HRCT imaging and patient‑reported quality of life.

First Repeated Inhaled mRNA Dosing Beyond One Month

Management underscored a key milestone in tolerability, reporting that ARCT‑032 has now been dosed continuously for more than a month without major safety issues, a first for inhaled mRNA therapeutics. They attributed this to the company’s proprietary LUNAR particle chemistry and mRNA purification, and emphasized that patients are dosing at home without steroid co‑treatment, which could prove a competitive differentiator if efficacy holds.

Regulatory Pathway Clarifies for ARCT‑810 in OTC Deficiency

For ARCT‑810, a therapy targeting ornithine transcarbamylase deficiency, Arcturus completed Type C meetings with the FDA and received what it called clear direction toward a pediatric pivotal path. The company is now gathering additional exploratory data, including from 0.3 and 0.5 dose groups, and plans an end‑of‑Phase II meeting in the second half of 2026 to solidify its pediatric development strategy.

Preclinical and Translational Evidence Bolsters CF Strategy

Executives highlighted extensive preclinical work supporting ARCT‑032, including data showing LNP stability in sputum and effective delivery to bronchial epithelial cells in mice, ferrets and nonhuman primates. They also cited optimized nebulizer particle size for lung distribution and prior HRCT scans suggesting mucus‑plug reductions, which may tie to future improvements in lung function metrics.

KOSTAIVE Partner Meiji Advances Commercial Manufacturing

On the commercial front, Japanese partner Meiji is actively manufacturing KOSTAIVE, a self‑amplifying mRNA COVID vaccine, in a two‑dose vial format for the 2026–2027 season. While Arcturus will not guide the market on sales, the company framed Meiji’s preparation as validation of its platform and an additional, though indirect, source of potential future revenue.

Leadership Bench Deepened With New CFO and CMO

Arcturus continued to reshape its leadership team, appointing Dennis Mulroy as chief financial officer and Dr. Alan Cohen as chief medical officer. Management portrayed these hires as strategically important, saying the mix of financial, clinical and regulatory experience will be critical as the company navigates pivotal trials and potential commercialization decisions.

Cash Runway Extends Beyond Mid‑2028

The company ended March 31, 2026 with $213.4 million in cash, cash equivalents and restricted cash, down from $232.8 million at year‑end 2025. Despite this quarter‑over‑quarter decline, management reiterated that its current resources should fund operations beyond the second quarter of 2028, covering planned milestones in cystic fibrosis and OTC deficiency.

Revenue Falls Sharply on Collaboration Reset

Quarterly revenue declined by $27.3 million year over year, driven largely by lower contribution from the CSL collaboration as Arcturus shifts its focus toward rare disease clinical programs. The company framed this drop as a by‑product of portfolio reprioritization rather than a sign of weakening demand for its platform, but investors will likely watch for alternative revenue sources.

Quarterly Cash Burn Highlights Spending Discipline Needs

The cash balance fell by $19.4 million, or roughly 8.3%, between December 31, 2025 and March 31, 2026, reflecting ongoing development spend. While the extended runway offers a buffer, the trend underscores the importance of disciplined capital allocation as late‑stage trials and manufacturing preparations drive higher cash requirements.

Cost Cuts and Headcount Reductions Signal Tightening

Arcturus reported year‑over‑year declines of $13.4 million in R&D expenses and $1.8 million in G&A, citing lower manufacturing and clinical costs, reduced stock‑based compensation and headcount reductions. Management positioned these moves as evidence of operational tightening and program prioritization, which may help stretch the company’s cash while still funding key assets.

LUNAR‑OTC Manufacturing Spend Offsets Part of Savings

Some of the R&D savings were offset by higher manufacturing costs related to the LUNAR‑OTC program, which supports development of ARCT‑810. This increased near‑term spending shows that even as overall expenses trend downward, individual programs entering advanced stages can still pressure the budget and influence burn.

Small, Open‑Label CF Trial Poses Interpretation Challenges

Management acknowledged that the 12‑week cystic fibrosis study is both open‑label and modest in size, with no placebo arm and enrollment capped at about 20 subjects. They also noted that regulators have yet to define success thresholds for FEV1 or LCI in this new modality and that important comparative LCI data from an external CF registry will not arrive until later this year or into 2027.

Modality and Competitive Risks Weigh on Inhaled CF Outlook

Arcturus addressed concerns after a competitor halted an inhaled CFTR mRNA trial, pointing to differences in technology and the absence of similar safety signals in its own data so far. Even so, management conceded that the competitor’s outcome underscores broader modality risk and could increase scrutiny from both regulators and prospective trial participants.

Enrollment Pace for CF Program Remains in Flux

The company said that enrollment cadence for the 12‑week CF trial should become clearer in the coming weeks as new global sites ramp up. With roughly 13 subjects enrolled in 2025 when the study was limited to the U.S., Arcturus signaled that timing could remain variable, which may influence how quickly investors see more mature efficacy and safety readouts.

Guidance Points to Long Runway and Key 2026 Milestones

Management reiterated guidance that the current $213.4 million cash position supports operations beyond the second quarter of 2028, even as revenue fell $27.3 million year over year and operating costs continued to adjust. Clinically, investors are told to watch the ongoing ARCT‑032 12‑week Phase II, further ARCT‑810 dose‑expansion data and a planned end‑of‑Phase II FDA meeting in the second half of 2026, while commercially Meiji’s KOSTAIVE production sets up potential future platform validation.

Arcturus’ earnings call painted a picture of a company pressing ahead on high‑potential programs while managing through revenue volatility and early‑stage clinical risk. With a solid cash runway, clearer regulatory paths and an expanded leadership team, the near‑term story hinges on whether ARCT‑032 can translate its early safety and translational signals into meaningful clinical benefit, and whether ARCT‑810 can progress smoothly into pivotal pediatric studies.